Pfizer CEO Shares Companies Future Plans, Surely Affecting PFE Stock Price

Pfizer emerged as a prominent name as producer of Covid-19 vaccines and PFE stocks reflected good growth

American multinational pharmaceutical company Pfizer (PFE) has new plans to diversify its production overpassing the revenue and dependency from COVID-19 vaccine. In a recent interview with Yahoo Finance, chief executive officer of Pfizer, Albert Bourla speaks about the company’s future outlook—launching new products, investing in science, merger and acquisitions, etc. All those factors which would be playing a crucial role in effecting PFE stocks price.

During the interview, Pfizer CEO highlighted the significant revenue generated by the COVID-19 vaccines following the pandemic. The revenue would allow the company to move forwards towards investing in science. This way Pfizer could bring more products in line to their traditional production and eventually PFE stock price is expected to witness the positive result.

Counting on the company’s ambitions, Boural said to allocate about 25 billion USD as risk-adjusted revenue by 2030. The company has already gathered over 10 billion USD. Moreover, he cited the internal pipeline of the company as the biggest competitive advantage.

Given their ability, the company is planning to bring ten new medicines by next year. These medicines would include five new vaccines, two oncology medicines and two immunoinflation medicines. This would be an unprecedented move for the company as Pfizer CEO told the traditional company used to produce generally one or two products every year.

In 2021, Pfizer reported to have an overall revenue of 81 billion USD which was only decreasing till the time. PFE stock price also went as high as 59.48 USD by December 2021. The company generated a significant revenue after the Covid-19 vaccine which now has seen considerable decline and still continues to drop.

Pfizer has plans to launch Comirnaty and Paxloid in upcoming months which will be replacing Covid-19 revenue generation. The company estimates Comirnaty would generate about 32 billion USD and Paxloid would end up making 22 billion USD in revenue. The projected revenue generation by both the products is over half of Pfizer’s overall revenue in 2021. If the estimation goes right, the products’ success would be making PFE stock price in good shape.

Bourla said the year would prove the world and to themselves their belief in both manufacturing and financial organizing strength. He stated the Pfizer employees witnessed their own potential development and production process of Comirnaty and also that they could also achieve the seemingly impossible goals.

Although several analysts do not agree with Bourla’s claim, the revenue generated by both the medicines. For instance, analyst Carter Gould said the medicines would be generating about 31 billion USD and 21.5 billion USD. He also added that in later months the sales would witness the decline of 43% and 51% respectively.

In both the cases, whether Pfizer CEO’s or analysts’ claim turned out to be right, PFE stock which is currently trading at 43.11 USD, would be receiving far different experience.